A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.
Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.
09-15-2021 | ESC 2021 | Conference coverage | Video
David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors.